Literature DB >> 9529074

Inhibition of the production of anti-OspA borreliacidal antibody with T cells from hamsters vaccinated against Borrelia burgdorferi.

J R Jensen1, B K Du Chateau, E L Munson, S M Callister, R F Schell.   

Abstract

The serious morbidity associated with Lyme borreliosis has focused considerable effort on the development of a comprehensive vaccine for protection against infection with Borrelia burgdorferi. Induction of borreliacidal antibody by vaccination or infection has been shown to correlate with protection of humans and animals against infection with the Lyme spirochete. In this report, we showed that high levels of borreliacidal antibody (titer of 1,280) were produced in vitro when T and B cells from hamsters 14 days after vaccination were incubated with macrophages and B. burgdorferi. By contrast, T and B cells from hamsters 7 or 21 days after vaccination failed to initiate production of borreliacidal activity. Furthermore, the T cells from hamsters 7 or 21 days after vaccination inhibited the in vitro production of borreliacidal antibody when cocultured with T and B cells obtained from hamsters 14 days after vaccination. When cell-free supernatants from the suspensions of T and B cells from hamsters 14 days after vaccination were absorbed with recombinant OspA, they lost nearly all borreliacidal activity. The removal of anti-OspA antibody resulted in a decrease in borreliacidal titer from 1,280 to less than 4. These results demonstrate that T cells from vaccinated animals can prevent a sustained production of protective borreliacidal antibody.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9529074      PMCID: PMC108081     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

Review 1.  Current understanding of Borrelia burgdorferi infection, with emphasis on its prevention in dogs.

Authors:  J J Kazmierczak; F E Sorhage
Journal:  J Am Vet Med Assoc       Date:  1993-12-01       Impact factor: 1.936

2.  Ability of canine Lyme disease vaccine to protect hamsters against infection with several isolates of Borrelia burgdorferi.

Authors:  D A Jobe; S M Callister; L C Lim; S D Lovrich; R F Schell
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

3.  Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine.

Authors:  D Keller; F T Koster; D H Marks; P Hosbach; L F Erdile; J P Mays
Journal:  JAMA       Date:  1994-06-08       Impact factor: 56.272

4.  The 39-kilodalton protein of Borrelia burgdorferi: a target for bactericidal human monoclonal antibodies.

Authors:  M Scriba; J S Ebrahim; T Schlott; H Eiffert
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

5.  Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen.

Authors:  W S Probert; R B LeFebvre
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

6.  Monoclonal antibodies with in vitro borreliacidal activities define the outer surface proteins A and B of Borrelia burgdorferi.

Authors:  M Moskophidis; B Luther
Journal:  Zentralbl Bakteriol       Date:  1993-06

7.  Animal and human antibodies reactive with the outer surface protein A and B of Borrelia burgdorferi are borreliacidal, in vitro, in the presence of complement.

Authors:  V Sambri; S Armati; R Cevenini
Journal:  FEMS Immunol Med Microbiol       Date:  1993-06

8.  Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection.

Authors:  V Preac-Mursic; B Wilske; E Patsouris; S Jauris; G Will; E Soutschek; S Rainhardt; G Lehnert; U Klockmann; P Mehraein
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

9.  Cross-reactivity between Borrelia burgdorferi flagellin and a human axonal 64,000 molecular weight protein.

Authors:  L H Sigal
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

10.  Development of destructive arthritis in vaccinated hamsters challenged with Borrelia burgdorferi.

Authors:  L C Lim; D M England; B K DuChateau; N J Glowacki; J R Creson; S D Lovrich; S M Callister; D A Jobe; R F Schell
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

View more
  3 in total

1.  Cyclooxygenase-1 orchestrates germinal center formation and antibody class-switch via regulation of IL-17.

Authors:  Victoria A Blaho; Matthew W Buczynski; Edward A Dennis; Charles R Brown
Journal:  J Immunol       Date:  2009-11-01       Impact factor: 5.422

2.  Interleukin-23 is required for development of arthritis in mice vaccinated and challenged with Borrelia species.

Authors:  Nicholas J Kotloski; Dean T Nardelli; Sara Heil Peterson; Jose R Torrealba; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

3.  Neutralization of gamma interferon augments borreliacidal antibody production and severe destructive Lyme arthritis in C3H/HeJ mice.

Authors:  Erik L Munson; David J DeCoster; Dean T Nardelli; Douglas M England; Steven M Callister; Ronald F Schell
Journal:  Clin Diagn Lab Immunol       Date:  2004-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.